Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Infarction | 22 | 2022 | 129 | 2.310 |
Why?
|
Angioplasty, Balloon, Coronary | 17 | 2022 | 36 | 2.210 |
Why?
|
ST Elevation Myocardial Infarction | 3 | 2022 | 9 | 1.520 |
Why?
|
Percutaneous Coronary Intervention | 3 | 2022 | 24 | 1.330 |
Why?
|
Coronary Restenosis | 5 | 2015 | 11 | 1.170 |
Why?
|
Stents | 11 | 2004 | 80 | 1.040 |
Why?
|
Antigens, CD34 | 6 | 2018 | 12 | 0.970 |
Why?
|
Stem Cell Transplantation | 5 | 2018 | 38 | 0.950 |
Why?
|
Cicatrix | 1 | 2022 | 7 | 0.820 |
Why?
|
Nanoparticles | 1 | 2022 | 11 | 0.820 |
Why?
|
No-Reflow Phenomenon | 1 | 2022 | 1 | 0.790 |
Why?
|
Electrocardiography | 6 | 2015 | 101 | 0.780 |
Why?
|
Brachytherapy | 5 | 2004 | 51 | 0.750 |
Why?
|
Myocardial Ischemia | 3 | 2017 | 37 | 0.720 |
Why?
|
Myocardium | 9 | 2018 | 95 | 0.670 |
Why?
|
Cardiac Catheterization | 4 | 2017 | 61 | 0.630 |
Why?
|
MicroRNAs | 2 | 2015 | 52 | 0.590 |
Why?
|
Triage | 2 | 2015 | 18 | 0.580 |
Why?
|
Drug-Eluting Stents | 2 | 2015 | 15 | 0.570 |
Why?
|
Heart Injuries | 1 | 2017 | 2 | 0.570 |
Why?
|
Body Surface Potential Mapping | 1 | 2017 | 3 | 0.570 |
Why?
|
Stem Cells | 4 | 2022 | 40 | 0.570 |
Why?
|
Heart Aneurysm | 1 | 2017 | 8 | 0.560 |
Why?
|
Heart Failure, Systolic | 1 | 2016 | 6 | 0.550 |
Why?
|
Heart Ventricles | 1 | 2017 | 96 | 0.530 |
Why?
|
Cell- and Tissue-Based Therapy | 4 | 2016 | 12 | 0.530 |
Why?
|
Angina Pectoris | 5 | 2018 | 13 | 0.530 |
Why?
|
Humans | 51 | 2022 | 25692 | 0.520 |
Why?
|
Emergency Service, Hospital | 4 | 2015 | 245 | 0.520 |
Why?
|
Vascular Remodeling | 1 | 2015 | 4 | 0.500 |
Why?
|
Vascular System Injuries | 1 | 2015 | 5 | 0.500 |
Why?
|
Catheters | 2 | 2021 | 17 | 0.460 |
Why?
|
Early Diagnosis | 1 | 2014 | 60 | 0.460 |
Why?
|
Coronary Angiography | 7 | 2022 | 67 | 0.450 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 9 | 0.420 |
Why?
|
Needles | 1 | 2012 | 12 | 0.420 |
Why?
|
Inpatients | 1 | 2014 | 132 | 0.410 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2016 | 39 | 0.410 |
Why?
|
Ventricular Function, Left | 6 | 2016 | 36 | 0.400 |
Why?
|
Middle Aged | 32 | 2018 | 8403 | 0.390 |
Why?
|
Animals | 12 | 2022 | 3510 | 0.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2012 | 95 | 0.380 |
Why?
|
Male | 38 | 2018 | 13917 | 0.370 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2016 | 48 | 0.360 |
Why?
|
Heart Failure | 4 | 2016 | 166 | 0.360 |
Why?
|
Graft Occlusion, Vascular | 3 | 2004 | 19 | 0.340 |
Why?
|
Coronary Stenosis | 3 | 2004 | 16 | 0.340 |
Why?
|
Treatment Outcome | 22 | 2021 | 3231 | 0.340 |
Why?
|
Myocardial Revascularization | 3 | 2004 | 15 | 0.330 |
Why?
|
Coronary Disease | 5 | 2003 | 56 | 0.330 |
Why?
|
Time Factors | 10 | 2016 | 1336 | 0.320 |
Why?
|
Aged | 26 | 2018 | 8501 | 0.320 |
Why?
|
Strontium Radioisotopes | 3 | 2003 | 7 | 0.310 |
Why?
|
Female | 31 | 2018 | 14273 | 0.310 |
Why?
|
Poloxalene | 4 | 1996 | 4 | 0.300 |
Why?
|
Transplantation, Autologous | 6 | 2018 | 151 | 0.290 |
Why?
|
Follow-Up Studies | 14 | 2015 | 1689 | 0.280 |
Why?
|
Cardiomyopathy, Dilated | 3 | 2016 | 7 | 0.280 |
Why?
|
Laser Therapy | 2 | 2004 | 10 | 0.280 |
Why?
|
Gastric Fundus | 1 | 2006 | 2 | 0.280 |
Why?
|
Gastric Fistula | 1 | 2006 | 5 | 0.270 |
Why?
|
Coronary Artery Disease | 5 | 2016 | 126 | 0.270 |
Why?
|
Electrodes | 1 | 2006 | 12 | 0.270 |
Why?
|
Pericardium | 1 | 2006 | 18 | 0.270 |
Why?
|
Defibrillators, Implantable | 1 | 2006 | 9 | 0.270 |
Why?
|
Myocardial Reperfusion | 3 | 1996 | 5 | 0.250 |
Why?
|
Double-Blind Method | 10 | 2016 | 396 | 0.240 |
Why?
|
Myocardial Reperfusion Injury | 3 | 1995 | 8 | 0.240 |
Why?
|
Platelet Membrane Glycoprotein IIb | 1 | 2004 | 1 | 0.240 |
Why?
|
Integrin beta3 | 1 | 2004 | 3 | 0.240 |
Why?
|
Myocardial Stunning | 1 | 2004 | 2 | 0.230 |
Why?
|
Heart Transplantation | 1 | 2004 | 29 | 0.230 |
Why?
|
Blood Platelets | 1 | 2004 | 36 | 0.230 |
Why?
|
Embolism, Cholesterol | 1 | 2004 | 1 | 0.230 |
Why?
|
Vascular Diseases | 1 | 2004 | 40 | 0.230 |
Why?
|
Echocardiography | 3 | 2017 | 88 | 0.220 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 68 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 102 | 0.210 |
Why?
|
Exercise Tolerance | 3 | 2018 | 30 | 0.210 |
Why?
|
Receptors, Fc | 1 | 2022 | 9 | 0.210 |
Why?
|
Complement Activation | 1 | 2022 | 10 | 0.210 |
Why?
|
Epitopes | 1 | 2022 | 44 | 0.200 |
Why?
|
Blood Substitutes | 3 | 1995 | 3 | 0.200 |
Why?
|
Fluorocarbons | 3 | 1995 | 11 | 0.200 |
Why?
|
Echocardiography, Doppler | 2 | 2001 | 21 | 0.200 |
Why?
|
Heart | 2 | 1994 | 57 | 0.200 |
Why?
|
Macrophages | 1 | 2022 | 97 | 0.200 |
Why?
|
Atherectomy, Coronary | 1 | 2021 | 2 | 0.190 |
Why?
|
Mammary Arteries | 1 | 2021 | 4 | 0.190 |
Why?
|
Wound Healing | 1 | 2022 | 150 | 0.190 |
Why?
|
Cytokines | 1 | 2022 | 212 | 0.180 |
Why?
|
Thrombolytic Therapy | 2 | 2002 | 48 | 0.180 |
Why?
|
Mice | 2 | 2022 | 1345 | 0.170 |
Why?
|
Prospective Studies | 11 | 2016 | 1633 | 0.170 |
Why?
|
Swine | 2 | 2012 | 71 | 0.160 |
Why?
|
Genetic Therapy | 2 | 2013 | 75 | 0.150 |
Why?
|
Marital Status | 1 | 2018 | 7 | 0.150 |
Why?
|
Angioplasty, Balloon | 5 | 2004 | 13 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 209 | 0.150 |
Why?
|
Mortality | 1 | 2018 | 80 | 0.150 |
Why?
|
Injections, Intramuscular | 2 | 2018 | 7 | 0.140 |
Why?
|
Radionuclide Ventriculography | 1 | 2017 | 1 | 0.140 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 341 | 0.140 |
Why?
|
Bone Marrow Transplantation | 1 | 2016 | 22 | 0.140 |
Why?
|
Endothelial Progenitor Cells | 1 | 2016 | 1 | 0.140 |
Why?
|
Blood Vessel Prosthesis Implantation | 4 | 2004 | 21 | 0.140 |
Why?
|
Cardiomyopathies | 1 | 2016 | 28 | 0.130 |
Why?
|
Dogs | 7 | 1996 | 176 | 0.130 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 217 | 0.130 |
Why?
|
Oxygen Inhalation Therapy | 1 | 1995 | 18 | 0.130 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2015 | 6 | 0.120 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2015 | 7 | 0.120 |
Why?
|
Blood Cells | 1 | 2015 | 4 | 0.120 |
Why?
|
Hospital Design and Construction | 1 | 2015 | 5 | 0.120 |
Why?
|
Stroke Volume | 4 | 2002 | 49 | 0.120 |
Why?
|
Coronary Circulation | 5 | 1996 | 25 | 0.120 |
Why?
|
Patient Transfer | 1 | 2014 | 22 | 0.120 |
Why?
|
Beta Particles | 3 | 2003 | 6 | 0.120 |
Why?
|
Atherosclerosis | 1 | 2015 | 55 | 0.120 |
Why?
|
Gene Transfer Techniques | 2 | 2005 | 25 | 0.110 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2016 | 30 | 0.110 |
Why?
|
Equipment Design | 2 | 2012 | 139 | 0.110 |
Why?
|
Referral and Consultation | 1 | 2014 | 86 | 0.110 |
Why?
|
Biomarkers | 2 | 2016 | 554 | 0.110 |
Why?
|
Fibrinolytic Agents | 4 | 2010 | 53 | 0.110 |
Why?
|
Angina, Stable | 1 | 2013 | 2 | 0.110 |
Why?
|
Retrospective Studies | 3 | 2015 | 3220 | 0.110 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 10 | 0.110 |
Why?
|
Plasmids | 1 | 2013 | 37 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 3 | 2006 | 698 | 0.100 |
Why?
|
Treatment Failure | 2 | 2003 | 154 | 0.100 |
Why?
|
Radiography, Interventional | 1 | 2012 | 22 | 0.100 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 71 | 0.100 |
Why?
|
Fluoroscopy | 1 | 2012 | 45 | 0.100 |
Why?
|
Cell Survival | 1 | 2012 | 110 | 0.100 |
Why?
|
Models, Animal | 1 | 2012 | 110 | 0.100 |
Why?
|
Radiography | 2 | 2004 | 574 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 311 | 0.100 |
Why?
|
Exercise Test | 3 | 2016 | 103 | 0.100 |
Why?
|
Length of Stay | 1 | 2014 | 300 | 0.100 |
Why?
|
Early Medical Intervention | 1 | 2012 | 13 | 0.100 |
Why?
|
Immunohistochemistry | 1 | 2012 | 341 | 0.100 |
Why?
|
Combined Modality Therapy | 5 | 2004 | 281 | 0.100 |
Why?
|
Registries | 2 | 2010 | 170 | 0.090 |
Why?
|
Patient Care Team | 1 | 2012 | 130 | 0.090 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2010 | 9 | 0.090 |
Why?
|
Sirolimus | 1 | 2010 | 18 | 0.080 |
Why?
|
Adult | 11 | 2016 | 7336 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2004 | 913 | 0.080 |
Why?
|
Thoracotomy | 2 | 2006 | 25 | 0.080 |
Why?
|
Disease Models, Animal | 3 | 2004 | 584 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 124 | 0.080 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2005 | 12 | 0.070 |
Why?
|
Injections | 3 | 2013 | 43 | 0.070 |
Why?
|
Collateral Circulation | 3 | 1999 | 5 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 1084 | 0.070 |
Why?
|
Stroke | 2 | 2016 | 259 | 0.070 |
Why?
|
Pilot Projects | 3 | 2004 | 392 | 0.070 |
Why?
|
Risk Assessment | 3 | 2004 | 618 | 0.070 |
Why?
|
Radiography, Thoracic | 1 | 2006 | 25 | 0.070 |
Why?
|
Equipment Failure | 1 | 2006 | 38 | 0.070 |
Why?
|
Foreign-Body Migration | 1 | 2006 | 18 | 0.070 |
Why?
|
Device Removal | 1 | 2006 | 85 | 0.070 |
Why?
|
Renal Circulation | 1 | 1985 | 2 | 0.060 |
Why?
|
Survival Rate | 2 | 2004 | 308 | 0.060 |
Why?
|
Tryptamines | 1 | 2005 | 1 | 0.060 |
Why?
|
Oxazolidinones | 1 | 2005 | 1 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2004 | 284 | 0.060 |
Why?
|
Norepinephrine | 1 | 1985 | 27 | 0.060 |
Why?
|
Migraine Disorders | 1 | 2005 | 19 | 0.060 |
Why?
|
Dopamine | 1 | 1985 | 85 | 0.060 |
Why?
|
Infusions, Intravenous | 3 | 2009 | 49 | 0.060 |
Why?
|
Peripheral Vascular Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
Ischemia | 1 | 2004 | 19 | 0.060 |
Why?
|
Extremities | 1 | 2004 | 23 | 0.060 |
Why?
|
Neutrophils | 2 | 1995 | 89 | 0.060 |
Why?
|
Thromboembolism | 1 | 2004 | 17 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2003 | 443 | 0.060 |
Why?
|
Ultrasonography, Doppler | 1 | 2004 | 13 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2004 | 6 | 0.060 |
Why?
|
Calcinosis | 1 | 2004 | 48 | 0.060 |
Why?
|
Risk Factors | 2 | 2016 | 2224 | 0.060 |
Why?
|
Lower Extremity | 1 | 2004 | 39 | 0.060 |
Why?
|
United States | 3 | 2016 | 1943 | 0.060 |
Why?
|
Hematologic Agents | 1 | 2003 | 3 | 0.060 |
Why?
|
Single-Blind Method | 1 | 2004 | 104 | 0.060 |
Why?
|
Angina, Unstable | 1 | 2003 | 10 | 0.060 |
Why?
|
Acute Disease | 1 | 2004 | 187 | 0.060 |
Why?
|
Lymphokines | 1 | 2003 | 7 | 0.060 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 8 | 0.060 |
Why?
|
Saphenous Vein | 1 | 2003 | 4 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2004 | 58 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2016 | 33 | 0.050 |
Why?
|
Rhodotorula | 1 | 2003 | 1 | 0.050 |
Why?
|
DNA | 1 | 2003 | 95 | 0.050 |
Why?
|
Endpoint Determination | 1 | 2003 | 21 | 0.050 |
Why?
|
Heart Valve Prosthesis | 1 | 2003 | 12 | 0.050 |
Why?
|
Endocarditis, Bacterial | 1 | 2003 | 10 | 0.050 |
Why?
|
Mycoses | 1 | 2003 | 21 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2003 | 110 | 0.050 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 52 | 0.050 |
Why?
|
Incidence | 2 | 2003 | 731 | 0.050 |
Why?
|
Necrosis | 2 | 1994 | 25 | 0.050 |
Why?
|
Death | 1 | 2003 | 35 | 0.050 |
Why?
|
Hypothermia, Induced | 1 | 2002 | 15 | 0.050 |
Why?
|
Illinois | 1 | 2003 | 223 | 0.050 |
Why?
|
Recurrence | 1 | 2003 | 275 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2003 | 299 | 0.050 |
Why?
|
Transplantation, Homologous | 1 | 2003 | 248 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2016 | 4459 | 0.050 |
Why?
|
Diastole | 1 | 2001 | 27 | 0.050 |
Why?
|
Neovascularization, Physiologic | 2 | 2016 | 19 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2004 | 827 | 0.050 |
Why?
|
Surface-Active Agents | 2 | 1999 | 5 | 0.040 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 1999 | 11 | 0.040 |
Why?
|
Quality of Life | 2 | 2016 | 600 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 157 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 1997 | 2 | 0.040 |
Why?
|
Cardiovascular Agents | 2 | 2012 | 27 | 0.040 |
Why?
|
Endothelin-1 | 1 | 1996 | 3 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 1 | 2016 | 1 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 1 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 1997 | 107 | 0.030 |
Why?
|
Placebos | 1 | 1996 | 68 | 0.030 |
Why?
|
Salvage Therapy | 1 | 1996 | 36 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2016 | 163 | 0.030 |
Why?
|
Hemorrhage | 1 | 2016 | 75 | 0.030 |
Why?
|
Risk | 1 | 2016 | 190 | 0.030 |
Why?
|
Academic Medical Centers | 2 | 2012 | 119 | 0.030 |
Why?
|
Clinical Competence | 1 | 1997 | 217 | 0.030 |
Why?
|
Recovery of Function | 1 | 2016 | 255 | 0.030 |
Why?
|
Chemotaxis, Leukocyte | 1 | 1994 | 9 | 0.030 |
Why?
|
Gases | 1 | 1994 | 5 | 0.030 |
Why?
|
Hospitals, Community | 1 | 2014 | 12 | 0.030 |
Why?
|
Hospitals, University | 1 | 2014 | 25 | 0.030 |
Why?
|
Ventricular Fibrillation | 1 | 1994 | 13 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 322 | 0.030 |
Why?
|
Time-to-Treatment | 1 | 2014 | 34 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2015 | 284 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2014 | 74 | 0.030 |
Why?
|
Patient-Centered Care | 1 | 2014 | 51 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2015 | 495 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 405 | 0.030 |
Why?
|
Rats | 1 | 2015 | 649 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 10 | 0.030 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2003 | 7 | 0.030 |
Why?
|
Angioplasty, Balloon, Laser-Assisted | 1 | 1992 | 1 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2013 | 71 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 84 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 325 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2012 | 10 | 0.020 |
Why?
|
Logistic Models | 2 | 2004 | 366 | 0.020 |
Why?
|
Critical Pathways | 1 | 2012 | 20 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 53 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2012 | 59 | 0.020 |
Why?
|
Disease Management | 1 | 2012 | 97 | 0.020 |
Why?
|
Survival Analysis | 2 | 2002 | 246 | 0.020 |
Why?
|
Quality Improvement | 1 | 2012 | 132 | 0.020 |
Why?
|
Off-Label Use | 1 | 2010 | 6 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 32 | 0.020 |
Why?
|
Injections, Intra-Arterial | 1 | 1989 | 5 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2010 | 23 | 0.020 |
Why?
|
Prednisone | 1 | 1989 | 58 | 0.020 |
Why?
|
Cohort Studies | 1 | 2013 | 1781 | 0.020 |
Why?
|
Streptokinase | 1 | 1987 | 1 | 0.020 |
Why?
|
Young Adult | 1 | 2013 | 1855 | 0.020 |
Why?
|
Shock, Septic | 1 | 1986 | 57 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 1985 | 9 | 0.020 |
Why?
|
Cardiac Output | 1 | 1985 | 11 | 0.020 |
Why?
|
Vascular Resistance | 1 | 1985 | 10 | 0.020 |
Why?
|
Drug Combinations | 1 | 1985 | 34 | 0.020 |
Why?
|
Serotonin Receptor Agonists | 1 | 2005 | 4 | 0.020 |
Why?
|
Heart Rate | 1 | 1985 | 109 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2004 | 126 | 0.010 |
Why?
|
Blood Pressure | 1 | 1985 | 185 | 0.010 |
Why?
|
Economics, Pharmaceutical | 1 | 2003 | 3 | 0.010 |
Why?
|
Factor Xa Inhibitors | 1 | 2003 | 5 | 0.010 |
Why?
|
Aortic Valve | 1 | 2003 | 25 | 0.010 |
Why?
|
Antifungal Agents | 1 | 2003 | 43 | 0.010 |
Why?
|
Safety | 1 | 2002 | 40 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2002 | 207 | 0.010 |
Why?
|
Radionuclide Angiography | 1 | 2002 | 1 | 0.010 |
Why?
|
Manometry | 1 | 2001 | 14 | 0.010 |
Why?
|
Random Allocation | 1 | 2002 | 116 | 0.010 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2001 | 16 | 0.010 |
Why?
|
Hemodynamics | 1 | 2001 | 57 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 69 | 0.010 |
Why?
|
Patient Dropouts | 1 | 2000 | 22 | 0.010 |
Why?
|
Poloxamer | 1 | 1999 | 3 | 0.010 |
Why?
|
Computer Systems | 1 | 1999 | 7 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1999 | 38 | 0.010 |
Why?
|
Prognosis | 1 | 2002 | 739 | 0.010 |
Why?
|
Reoperation | 1 | 2003 | 818 | 0.010 |
Why?
|
Credentialing | 1 | 1997 | 7 | 0.010 |
Why?
|
Hospitals, Urban | 1 | 1997 | 31 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 1997 | 26 | 0.010 |
Why?
|
Health Services Research | 1 | 1997 | 38 | 0.010 |
Why?
|
Odds Ratio | 1 | 1997 | 244 | 0.010 |
Why?
|
Hospital Mortality | 1 | 1997 | 131 | 0.010 |
Why?
|
Creatinine | 1 | 1996 | 47 | 0.010 |
Why?
|
Rabbits | 1 | 1995 | 184 | 0.010 |
Why?
|
Chicago | 1 | 1997 | 869 | 0.010 |
Why?
|
Fibroblasts | 1 | 1989 | 55 | 0.010 |
Why?
|
Lymphocytes | 1 | 1989 | 57 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 1989 | 152 | 0.010 |
Why?
|
Angiography | 1 | 1987 | 29 | 0.000 |
Why?
|
Anemia, Aplastic | 1 | 1986 | 1 | 0.000 |
Why?
|
Regional Blood Flow | 1 | 1986 | 8 | 0.000 |
Why?
|
Lactates | 1 | 1986 | 3 | 0.000 |
Why?
|
Oxygen Consumption | 1 | 1986 | 45 | 0.000 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1986 | 41 | 0.000 |
Why?
|
Neoplasms | 1 | 1986 | 224 | 0.000 |
Why?
|
Adolescent | 1 | 1986 | 2076 | 0.000 |
Why?
|